Stock Split History
ETFs Holding TERN »    TERN Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. Co. develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase 2a clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase 1 clinical trial for the treatment of NASH. According to our Terns Pharmaceuticals stock split history records, Terns Pharmaceuticals has had 1 split.
Terns Pharmaceuticals stock split history picture
Terns Pharmaceuticals (TERN) has 1 split in our Terns Pharmaceuticals stock split history database. The split for TERN took place on May 08, 2000. This was a 2 for 1 split, meaning for each share of TERN owned pre-split, the shareholder now owned 2 shares. For example, a 1000 share position pre-split, became a 2000 share position following the split.

When a company such as Terns Pharmaceuticals splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.

Looking at the Terns Pharmaceuticals stock split history from start to finish, an original position size of 1000 shares would have turned into 2000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Terns Pharmaceuticals shares, starting with a $10,000 purchase of TERN, presented on a split-history-adjusted basis factoring in the complete Terns Pharmaceuticals stock split history. Terns Pharmaceuticals split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 02/05/2021
End date: 05/17/2021
Start price/share: $18.39
End price/share: $16.37
Dividends collected/share: $0.00
Total return: -10.98%
Annualized Gain: -40.09%
Starting investment: $10,000.00
Ending investment: $8,902.00
Years: 0.27
Date Ratio
05/08/20002 for 1
LM Funding America, Inc. (LMFA)
Foxby Corp. (XFXBX)
InspireMD, Inc. (NSPR)
Aviat Networks, Inc. (AVNW)
Guardion Health Sciences, Inc. (GHSI)
China SXT Pharmaceuticals, Inc. (SXTC)
VYNE Therapeutics Inc. (VYNE)
The Sherwin-Williams Company (SHW)
Horizons US Marijuana Index ETF (HMUS)
MicroSectors FANG+ ETNs due January 8, 2038 (FNGS)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »
Funds Holding Terns Pharmaceuticals

Terns Pharmaceuticals Stock Split History | www.StockSplitHistory.com | Copyright © 2013 - 2021, All Rights Reserved

Nothing in www.StockSplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.